Very recently, however, the combination of nivolumab with the anti-LAG3 antibody relatlimab has emerged as a potential front-line therapeutic option for advanced melanoma with a more favourable toxicity profile than ipilimumab-nivolumab and significant biological activity in high-risk subgroups 66. This evidence concerns the gene LAG3 and melanoma.